CD4 and HIV-1 infection: With a particular focus on the newly developed HSV-2 antiviral drug pritelivir, we showed that certain doses may decrease the risk factors linked with HIV-1 infection susceptibility, namely CD4+ T cell count and HSV-2 lesion severity.